@FiercePharma: China's pharma industry blames toxic capsules on super-aggressive tendering, says corner-cutting won't stop. Report | Follow @FiercePharma
>Germany should nix its rebates and price limits now that its insurers are profitable, Sanofi operations chief Hanspeter Spek told Der Tagesspiegel. Report
>Pfizer partner Takeda will stop selling 13 of the U.S.-based drugmaker's products in Japan as Pfizer takes over their marketing; the two will still work together on Enbrel. Report
>Teva's new higher-dose version of Copaxone, designed for injection only three times weekly, performed well in a new study, raising the company's hopes of prolonging sales of its big-selling drug. Report
>Antibiotic use in children and adolescents is down 7% from 2002 levels, while prescriptions for ADHD drugs have jumped, an FDA report finds. Report
>India's Piramal Healthcare is in early talks to buy the contract drugmaker Cambridge Major Laboratories for up to $200 million, the Financial Express reported. Report
>Almost half of Pradaxa patients requiring surgery were able to stop therapy for just two days to minimize bleeding, compared with 11% on rival anticoagulant warfarin, a study found. Release
> FDA keeps door open to pharmacy versions of KV's Makena. More
> Biotest prepared to exit Greece for non-payment. Story
> Cipla chief aims for more cut-rate cancer drugs. Article
Biotech News
@FierceBiotech: The Fierce team has landed in Boston. Check out our dedicated BIO2012 page. Special Coverage | Follow @FierceBiotech
@JohnCFierce: Quintiles (CRO) is expanding in China, building a regional HQ in Shanghai. Release | Follow @JohnCFierce
@RyanMFierce: Roche does an encore Alzheimer's deal with AC Immune worth up to $420M, focused on anti-Tau antibodies. More | Follow @RyanMFierce
> BIO's James Greenwood sees industry optimism returning. Report
> Roche snags another Alzheimer's antibody from AC Immune in $418M-plus deal. News
> Ambrx inks $303M 'smart bomb' development pact with Merck. More
> Infinity Pharma writes off lead drug after two more failed studies. Article
Medical Devices News
@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev
> Oxford Immunotec pulls in $28M to boost TB Dx test. Story
> How can the FDA fix its device-approval process? Article
> Industry may be overstating effect of device tax. More
Biotech IT News
> Harvard IDs key human-hosted bugs with computer systems. More
> Third Rock fuels $41M launch of Bay Area biotech. Item
> Africa goes mobile to tackle drug safety woes. Story
And Finally ... China's pharmaceutical industry blamed aggressive pricing policies for the corner-cutting that led to a flood of tainted gelatin capsules. Report